Cure and Fidelity Host a Healthcare Reverse Pitch in NYC

At 5:40 PM on November 17, the microphone at Cure is scheduled to pass to the investors. Cure and Fidelity Private Shares are bringing healthcare entrepreneurs and investors together in New York for The Reverse Pitch, an evening built around hearing what catches an investor's attention before the networking conversation begins.

The event runs from 5 to 7 PM EST at Cure, 345 Park Avenue South, New York, NY 10010. The announced participants include moderator Charlie Stephens of Fidelity and speakers Selin Altinok, PhD, of SOSV, alongside Deerfield Management Principals Eddie Yang and Moses Adubi. For founders preparing to explain both a healthcare innovation and the business around it, the format offers a chance to ask more specific questions about investor fit.

That opportunity sits in the agenda's sequence. Investors describe their priorities, then attendees have time to speak with one another while those explanations are fresh. The practical value will depend on how clearly the conversation connects an investor's interests with the evidence a founder can actually bring.

A short investor discussion with room to follow through

The Reverse Pitch's official program begins with an opening reception at 5 PM, followed by welcome remarks at 5:30 and a founder spotlight at 5:35. The investor conversation starts at 5:40, networking resumes at 6, and the evening closes at 7. Cure members attend free, while the listed non-member price is $20.

The discussion itself occupies a relatively small portion of the evening. That makes the surrounding conversations part of the editorial reason to pay attention. A founder who hears an investor explain an area of interest can use the later reception to ask about a particular milestone, describe a relevant problem, or establish whether a longer exchange makes sense.

Preparing for that sequence calls for some restraint. A founder could arrive with one unresolved question about how to present the company and listen for the information that makes the question sharper. Hearing a specific investment remit can help someone decide which part of a scientific or commercial story deserves a follow-up.

Cure describes the gathering as a meeting place for healthcare innovators, entrepreneurs, and investors, with drinks and light bites. The named founder spotlight participant has yet to be identified on the official page. Readers can review the current program and complete event registration through Cure's listing as the date approaches.

Three speakers across distinct healthcare disciplines

The announced investor lineup gives the conversation several starting points. Eddie Yang is a Principal on Deerfield's Therapeutics team, while Moses Adubi is a Principal on its Healthcare Services team. Those assignments matter because a discussion about a therapeutic program can involve a different set of operating questions from a discussion about delivering healthcare services.

For a founder, the useful listening exercise is to connect those disciplines to the company's own next decision. A scientific milestone, an operating requirement, and a financing conversation may intersect within one business. Hearing how investors describe their focus can help a founder organize those threads before asking someone to spend more time evaluating the company.

Selin Altinok, PhD, brings SOSV affiliation and a pharmacology background. SOSV's biography describes investment-diligence work and earlier involvement helping academic founders develop their research into businesses. That combination adds a relevant perspective for scientists working through the distance between a promising research result and a company that others can understand and assess.

Charlie Stephens will moderate, with Cure identifying his Fidelity role as VP Business Partner Manager. The moderator's opportunity is to make the differences among those perspectives concrete. Questions about which evidence changes an investor's assessment, or which milestone earns another conversation, would give founders something specific to carry into the reception that follows.

Fundraising preparation extends into the records

Fidelity Private Shares is an equity-management platform for private companies, with tools that include cap-table management, data rooms, and scenario modeling. Its presence gives the gathering a connection to the administrative work that accompanies a company's funding story. Ownership records and supporting documents become part of how that story can be examined when an initial conversation develops.

There is an operating implication here for founders and the people helping them raise capital. Listening to an investor's questions may reveal a gap in how the company explains its progress or organizes its supporting material. Identifying that gap early gives the team a more concrete preparation task before the next meeting.

Cure contributes a healthcare-focused setting for those exchanges. The organizer describes its New York campus as a home for healthcare organizations at different stages and discloses its affiliation with Deerfield. That relationship provides context for the venue and the two scheduled Deerfield speakers, while the published lineup also includes SOSV and Fidelity participation.

Healthcare founders, scientific entrepreneurs, and operators responsible for fundraising preparation have the clearest reason to examine the program. They can judge the fit against their own work, from explaining a research milestone to preparing a clearer account of how a healthcare business operates. Each has a different question to bring, which is part of what can make a focused room valuable.

What founders can carry into the networking reception

A useful preparation question for this evening is where an investor's current focus intersects with the company's next piece of evidence. The reverse-pitch format gives founders a way to listen for that intersection as investors explain their priorities. A later introduction can then begin with a specific point from the discussion and move toward the company's relevant work.

The same approach can help operators attending alongside a founder. One person may hear a question about the scientific program, while another recognizes work needed in the company's records or commercial explanation. Comparing those observations after the discussion could produce a more focused preparation agenda for the team.

The schedule leaves an hour between the start of the networking reception and the 7 PM close. At Cure on November 17, the discussion's most consequential detail may be the question a founder is ready to ask when that hour begins. The answer could shape the work that follows the next morning, when the company returns to its evidence, its documents, and the next investor conversation.